Chicago Equity Partners LLC Has $20.01 Million Stake in Pfizer Inc. (PFE)

Chicago Equity Partners LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 35.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 595,621 shares of the biopharmaceutical company’s stock after selling 325,680 shares during the period. Chicago Equity Partners LLC’s holdings in Pfizer were worth $20,007,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer in the second quarter valued at about $102,000. D. Scott Neal Inc. grew its position in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the period. Herndon Capital Management LLC bought a new position in Pfizer during the second quarter valued at about $120,000. Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer during the first quarter valued at about $121,000. Finally, Private Vista LLC grew its position in Pfizer by 2,277.3% during the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 190,933 shares during the period. Institutional investors own 69.89% of the company’s stock.

Several research firms recently weighed in on PFE. Deutsche Bank set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 10th. Barclays set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $38.77.

In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders sold 60,280 shares of company stock valued at $2,118,988 over the last 90 days. 0.06% of the stock is owned by company insiders.

Pfizer Inc. (NYSE PFE) traded down $0.43 during mid-day trading on Wednesday, hitting $35.63. 22,320,600 shares of the stock were exchanged, compared to its average volume of 19,989,418. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a one year low of $30.51 and a one year high of $36.78. The company has a market capitalization of $211,960.00, a price-to-earnings ratio of 14.42, a P/E/G ratio of 2.54 and a beta of 1.01.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. During the same period last year, the business earned $0.61 earnings per share. Pfizer’s revenue was up .9% compared to the same quarter last year. analysts anticipate that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were given a $0.32 dividend. The ex-dividend date was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s dividend payout ratio (DPR) is currently 78.53%.

ILLEGAL ACTIVITY WARNING: This article was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2017/12/06/chicago-equity-partners-llc-has-20-01-million-stake-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply